Aarti Pharmalabs Reports Q2 Consolidated Net Profit Of ₹75.4 Crore Vs ₹27.9 Crore YoY

Market snapshot: Aarti Pharmalabs Limited announced its financial results for the second quarter ended September 30, 2026. The company reported a consolidated net profit of ₹75.40 crore, compared to ₹27.90 crore in the corresponding period of the previous fiscal year.

Data Snapshot

• Q2 consolidated net profit reached ₹75.40 crore compared to ₹27.90 crore in the prior-year period.
• Q1 FY27 consolidated net profit stood at ₹76.14 crore, reflecting a 65.4% YoY surge.

What's Changed

• Q2 consolidated net profit expanded to ₹75.40 crore compared to ₹27.90 crore YoY.
• Sequential profitability remained steady following a consolidated net profit of ₹76.14 crore in Q1 FY27.

Key Takeaways

• Consolidated net profit for Q2 rose to ₹75.40 crore from ₹27.90 crore YoY.
• The results sustain the earnings momentum established during Q1 FY27.
• Growth aligns with ongoing commercialization efforts across pharmaceutical intermediates and CDMO lines.

SAHI Perspective

Aarti Pharmalabs has delivered strong bottom-line expansion in Q2, building on its solid Q1 performance. The sustained profit growth indicates improving asset utilization and stable operating efficiency across its pharmaceutical manufacturing units.

Market Implications

The quarterly earnings reflect healthy demand in the API and CDMO verticals, offering positive earnings visibility as current capital expenditure projects progress toward operationalization.

Trading Signals

Market Bias: Bullish

Q2 consolidated net profit surged to ₹75.40 crore from ₹27.90 crore YoY, sustaining earnings momentum established by Q1 net profit of ₹76.14 crore.

Overweight: Pharmaceuticals, CDMO & APIs

Trigger Factors:

• Margin stability in core API and intermediate products
• Commissioning of planned CDMO production capacities

Time Horizon: Near-term (0-3 months)

Industry Context

Indian API and CDMO suppliers are benefitting from ongoing global supply chain diversification and sustained demand for high-value active ingredients, driving volume growth for compliant domestic manufacturers.

Key Risks to Watch

• Input cost fluctuations in chemical intermediates and energy overheads
• Commercial timeline execution for new CDMO capacity additions

Recent Developments

In August 2026, Aarti Pharmalabs reported a 65.4% YoY surge in Q1 net profit to ₹76.14 crore alongside a ₹149 crore capex plan to add 405 KL capacity for its CDMO and intermediate businesses.

Closing Insight

Backed by strong Q2 net profit figures and ongoing capacity expansion, Aarti Pharmalabs continues to build operational scale in key pharmaceutical supply chains.

High Performance Trading with SAHI.